fb777 vip login password

In a way, tariffs, sanctions and bans all boil down to one word: no. We’ve just had a month of “no”. No-vember, you could even say. But not all noes are the same. Tariffs, sanctions and bans are designed to achieve different things. This November, the words became confused, a scrambled negation. So it is with Donald Trump’s tariffs , promised during the election campaign as a way to protect American manufacturing interests in the face of competition from global trade. These promises spoke to the towns and cities gutted and citizens rendered jobless and hopeless as corporates offshored their business. They painted a picture of resurgent industry and innovation in America, leading to prosperity for working people. Trump’s tariff announcement wiped billions from the Australian sharemarket. Credit: The idea of tariffs has economists in a flap. As you are sure to have heard them patiently, if condescendingly, explain by now, tariffs are really taxes on consumers in the country that imposes them. They make imported goods more expensive, lowering the overall buying power of the average punter. In an economists’ paradise, our interests would be best served by removing trade barriers entirely and letting every country produce according to its ability and sell to others according to their need. Unfortunately, humanity has proven unworthy of this lofty ideal. In the real world, there are wars and chaos. In this world, a tariff can serve a strategic purpose – for instance, a country might put a tariff on the import of milk to protect its local milk producers. This ensures it always has access to the nutritious comestible, even if supply chains are cut off or relations with the supplying nations sour. Loading Trump isn’t yet president again, but he’s already described the tariffs he actually plans to make policy. When he gains office, at the end of January next year, he will slap a 25 per cent tariff on all goods imported from Canada and Mexico, along with another 10 per cent tariff on China. But here’s the perplexing thing: the purpose of these so-called tariffs is not to protect US industry (at least not any legal one) from cheaper goods from overseas. The tariffs Trump has announced since winning have been focused on curbing the importation of illegal drugs and stopping immigrants entering the US without permission. Trump posted on his social media platform, Truth Social, that his tariffs “will remain in effect until such time as Drugs, in particular Fentanyl, and all Illegal Aliens stop this Invasion of our Country!” Which reveals the problem: the word tariff doesn’t mean what Trump thinks it means. A tariff levied on all goods for the purposes of forcing a country to comply with international rules, such as respect for borders and prohibitions on narcotics, is not a tariff at all. It’s a sanction. Sorry, not sorry, for splitting that hair. Confounding tariffs and sanctions is a serious matter, which will lead to poor policy outcomes and worse living conditions for your average world citizen. Only pedantry can save us now. Loading It could save sex, too, and the joy of human relations. To celebrate this No-vember, American women unhappy with Donald Trump’s win imported the 4B movement from South Korea. The name translates to the Four Noes – because adherents say no to dating men, no to marrying men, no to having sex with men, and no to having children with men (which presumably means no entirely to the last, given the tricky gamete situation faced by our dioecious species). This is a classic case of imposing a sanction where a tariff would be better suited. It must be assumed that the women committing themselves to 4B are heterosexual women (otherwise there’s nothing to give up) who have decided, on the basis that some men have political or social attitudes that they disagree with, to place sanctions on the entire gender. Not only is this a neat illustration of the fact that sanctions can also have consequences for the sanctioning party – these women are denying their own urges to inflict a punishment on others – but it demonstrates the importance of choosing the right tariff, sanction or ban to achieve your objective. In this case, a tariff would be more beneficial. Instead of swearing off men entirely, heterosexual women (who want those things) could impose an extra cost on sex, dating, marriage and children by only engaging in those activities with men who treat women well and respect their physical autonomy. There are no rules that tariffs have to be levied in dollars and cents. Loading You could say that, before social norms changed, the tariff levied on sex used to be marriage; selecting for character was called being choosy. Sure, it’s harder to find a decent man than settle for one who’s handy, randy and willing. But as we’ve already established, while tariffs might protect something we consider desirable, they do it by making goods dearer for the consumer. At least, unlike sanctions, tariffs don’t render them unavailable entirely. So the power of pedantry to clarify the different types of “no” is crucial to getting the best out of national and social relations. But it could also create a better conversation around the so-called social media bans for under 16s. This legislation has been rammed through parliament just in time for parents to spend Christmas trying to explain it to their children. The trouble is, the ban is not a ban – it’s an attempt to respond to the damage that autoplay and algorithms are doing to attention spans and to discourage a scrolling spiral of harmful content. And that needs, somehow, to stop. Most people don’t necessarily want to ban social media; we want it to be better. Targeted modifications could help, but even more powerful would be a subscription fee that would force platforms to verify users through a credit card payment. So, yes, it would cost the consumer to fix social media. But if there’s one thing we can learn from this November, it’s that saying no – whether through tariffs, sanctions or bans – can, in the right circumstances, be worth the price. Parnell Palme McGuinness is managing director at campaigns firm Agenda C. She has done work for the Liberal Party and the German Greens. Save Log in , register or subscribe to save articles for later. License this article Trade wars Opinion Donald Trump Trump diplomacy China Parnell Palme McGuinness is managing director at campaigns firm Agenda C. She has done work for the Liberal Party and the German Greens. Most Viewed in Business Loading

The Sandbox and Animoca Brands Japan, subsidiaries of Animoca Brands, also participated in the investment, further solidifying the company’s support for Igloo Inc. Igloo’s subsidiary Cube Labs recently unveiled Abstract, an Ethereum scaling L2 solution explicitly designed for consumer-centric applications. With this investment, Animoca Brands aims to foster community engagement by facilitating cross-community marketing and collaboration between Abstract and Animoca Brands’ own Mocaverse. Pudgy Penguins, a popular NFT collection that debuted on Ethereum in 2021, has seen significant growth since its inception. Under the leadership of CEO Luca Schnetzler, who acquired the brand in 2022, Pudgy Penguins has expanded into physical merchandise, gaming, and even announced a social open world game called Pudgy World in 2023. Most recently, the company partnered with renowned web3 game developer Mythical Games to develop a mobile social party game called Pudgy Party. , commented: , added:DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DENTSPLY SIRONASpotify has 'pirated software, cheat codes and adult entertainment' problem

A stroke changed a teacher’s life. How a new electrical device is helping her moveParkinson's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amneal Pharma 11-21-2024 08:50 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parkinson's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market. The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parkinson's Disease Pipeline Report: https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years. •Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment •Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years. •In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson's Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research's network, will be a site for PhotoPharmics' LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson's symptoms. •In September 2024, AbbVie's recently acquired Parkinson's disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). •In December 2023, Gain Therapeutics, a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. •In December 2023, Vanqua Bio disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug VQ-101 as a potential treatment for Parkinson's disease linked to GBA1 mutations. Parkinson's Disease Overview Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control. Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include: •KM-819: FAScinate Therapeutics •Prasinezumab: Hoffmann-La Roche •P2B001: Pharma Two B Ltd. •NPT1220-478: Neuropore Therapies, Inc. •Dapansutrile: Olatec Therapeutics •UCB7853: UCB Biopharma •UB-312: Vaxxinity •Emrusolmin: Modag •PT320: Peptron •KDT-3594: Kissei Pharmaceutical •Tavapadon: Cerevel Therapeutics Parkinson's Disease Route of Administration Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Inhalation •Inhalation/Intravenous/Oral •Intranasal •Intravenous •Intravenous/ Subcutaneous •NA •Oral •Oral/intranasal/subcutaneous •Parenteral •Subcutaneous Parkinson's Disease Molecule Type Parkinson's Disease Products have been categorized under various Molecule types, such as •Antibody •Antisense oligonucleotides •Immunotherapy •Monoclonal antibody •Peptides •Protein •Recombinant protein •Small molecule •Stem Cell •Vaccine Parkinson's Disease Pipeline Therapeutics Assessment •Parkinson's Disease Assessment by Product Type •Parkinson's Disease By Stage and Product Type •Parkinson's Disease Assessment by Route of Administration •Parkinson's Disease By Stage and Route of Administration •Parkinson's Disease Assessment by Molecule Type •Parkinson's Disease by Stage and Molecule Type DelveInsight's Parkinson's Disease Report covers around 150+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parkinson's Disease Therapeutics Market include: Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others. Parkinson's Disease Pipeline Analysis: The Parkinson's Disease pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment. •Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parkinson's Disease Pipeline Market Drivers •Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market. Parkinson's Disease Pipeline Market Barriers •However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth. Scope of Parkinson's Disease Pipeline Drug Insight •Coverage: Global •Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others •Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others •Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies •Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parkinson's Disease Report Introduction 2. Parkinson's Disease Executive Summary 3. Parkinson's Disease Overview 4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment 5. Parkinson's Disease Pipeline Therapeutics 6. Parkinson's Disease Late Stage Products (Phase II/III) 7. Parkinson's Disease Mid Stage Products (Phase II) 8. Parkinson's Disease Early Stage Products (Phase I) 9. Parkinson's Disease Preclinical Stage Products 10. Parkinson's Disease Therapeutics Assessment 11. Parkinson's Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parkinson's Disease Key Companies 14. Parkinson's Disease Key Products 15. Parkinson's Disease Unmet Needs 16 . Parkinson's Disease Market Drivers and Barriers 17. Parkinson's Disease Future Perspectives and Conclusion 18. Parkinson's Disease Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market •Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market •Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight •Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market •Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market •Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Contact Us: Gaurav Bora gbora@delveinsight.com +91-9650213330 Healthcare Consulting https://www.delveinsight.com/consulting-services Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.EL SEGUNDO, Calif. -- The congregated as a team Wednesday for the first time since Sunday's win over the , only an important figure was missing from the group: . "LeBron is not with the team right now," Lakers coach JJ Redick said after practice. "He's out for personal reasons, excused absence." James because of soreness in his left foot. It was the first game James, 39, missed all season. With the schedule providing a break -- L.A. plays just two games in a 10-day stretch from Dec. 9-18 -- Redick gave the entire team Monday off and designated Tuesday as an optional "get what you need" day. Redick met with many of the Lakers' players individually Tuesday, but James was not present, the coach said. The coach was asked about the upcoming break on Sunday and made it clear he would give his players the freedom to use the time as they deemed fit. "Heck, if somebody wants to go spend a couple of nights in Santa Barbara and relax, that's fine too," Redick said after the Blazers game. "It's a quarter way through the season." Redick added that James is currently "taking some time" and he was unclear whether the 22-year veteran would be back with the team for their next game, Friday on the road against the . Lakers backup center said James' presence was missed, but he was not worried about him falling behind on the team's schemes because of his absence. "I mean, we know he already knows everything," Koloko said. "He's going to come back and he's still going to be the same. He's going to give everything on the court. "We just got to do our part and just get better so that when he comes back, he can just look at us and be like, 'Oh, yeah, [they] were actually working,' when he wasn't there. But we know he'll come back and just pick up everything. He's been in the NBA for a long time." On the season, James is averaging 23 points on 49.5% shooting (35.9% from 3), 9.1 assists and 8.0 rebounds. Redick said he is in constant communication with both James and his longtime athletic trainer, Mike Mancias, about managing the four-time MVP's workload as he nears his 40th birthday at the end of the month. "In game, he's asked for a sub a couple times because he's gassed," Redick said. "For us, we have to be cognizant as we play more and more games, just the cumulative effect of playing a lot of minutes and Sunday, being banged up with the foot thing, it felt like a good opportunity for him to get some rest." Redick added that Lakers starting shooting guard , who missed the past five games with a left pelvic injury, returned to practice Wednesday and was able to join his teammates for most of the drills. "I wouldn't call Austin a full participant," Redick said. "There was one thing that he sat out that we suggested ... that was probably not good for him, just due to the nature of the drill. It was particularly a physical drill and just want to be mindful of his pain tolerance. But he was full participant of all the 5-on-5, live stuff and all the breakdown drills." Reaves is considered day-to-day heading into the Minnesota game, according to Redick.

Real estate records, Dec. 1

ILWU provides hundreds of families with Thanksgiving dinner baskets

"Every Attack Makes Us Stronger": Gautam Adani Responds To US Allegations

Gov. Whitmer travels to Spain for trade mission to bring home investments, jobsWhat the Options Market Tells Us About Occidental Petroleum

North Carolina Republicans overrode a veto from outgoing Democratic Gov. Roy Cooper on Wednesday, passing SB 382, a controversial bill that systematically strips key powers from several statewide offices voters elected Democrats to in this year's election, per ABC 11. The vote, which saw widespread protests at the state capitol, was originally scheduled for Monday but was pushed out two days as the GOP legislature wrangled to get enough votes from reluctant members of the caucus. The bill is ostensibly about authorizing aid to areas devastated by Hurricane Helene earlier this year; however, among other things, it also strips Gov.-elect Josh Stein of the power to appoint the state board of elections , limits Attorney General-elect Jeff Jackson's authority to intervene in cases where the state legislature's actions are challenged in court, and eliminates Superintendent-elect Mo Green's powers to oversee the state's charter school system. ALSO READ: Agenda 47: Alarm sounded about Trump’s dystopian plans for his second term The bill also reconfigures the state court system to eliminate certain districts where judges commonly overrule GOP legislation, and cuts the amount of time voters have to cure defective ballots — which helped decide several close races in the Democrats' favor this year. In addition to electing several statewide Democrats, voters also stripped the GOP of its legislative supermajority; however, that supermajority moved to pass this legislation weeks before the new session was to be sworn in. "The people of western North Carolina are desperate for help from their state government," Stein said in a statement. "Yet, this bill is a power grab, not hurricane relief. It is despicable for the Republicans in the General Assembly to use folks' incredible need for aid to cloak their political pettiness. The legislature needs to step up and do its job. If they do, they will find a good-faith partner in me. I'm ready to get to work."Global Video Hosting Software Market Size, Share and Forecast By Key Players-Wistia, Vimeo, BombBomb, Cincopa, Vidyard

NEW YORK (AP) — A shoplifting ring that stole nearly $2 million in clothes and beauty products from Macy’s and other well-known stores in the U.S. and then resold them in New York City and the Dominican Republic has been busted, law enforcement officials announced Tuesday. Five New Yorkers have been charged with felony possession of stolen property, conspiracy and other related crimes, Queens District Attorney Melinda Katz said. The bust served as a reminder to shoppers as the holiday shopping season kicks off in earnest with Black Friday this week to make sure they are supporting legitimate establishments, she said. “When a deal seems too good to be true, I guarantee you, it’s too good to be true,” Katz said. Nationally, businesses lose roughly $100 billion and the average family pays $500 more a year because of the impact of organized retail theft, according to New York Gov. Kathy Hochul, who joined the district attorney and other law enforcement officials in Queens. The Democrat said the arrests also marked the first time anyone has been charged under a new criminal statute of fostering the sale of stolen goods that she recently signed into law to help crack down on retail theft. “This is real simple. We’ve had enough with criminals preying on our citizens,” Hochul said. “We are sick and tired of our citizens feeling they’re vulnerable to random crimes on the streets or these sophisticated organized crime rings. And we are coming after you.” Katz, the district attorney, said the group stole high-end makeup, perfume, beauty products, designer clothing and accessories from stores ranging from Macy’s to Victoria’s Secret, American Eagle, Sephora and Ulta Beauty over a roughly two-year period. The group’s leaders, married couple Cristopher Guzman and Yvelisse Guzman Batista, directed shoplifting crews to steal specific merchandise as they hit multiple stores in New York, New Jersey, Maryland and elsewhere along the East Coast, she said. They also paid truck drivers to divert products bound for retailers from manufacturer warehouses directly to locations under their control. The group, operating out of a home in Queens, then resold the merchandise online as well as at a brick-and-mortar boutique called Yvelisse Fashion in Santiago, a city in the Dominican Republic. Vince Scala, a lawyer for the couple and two of the other defendants, said his clients pleaded not guilty at their arraignment Saturday. They were released pending their next court date in January. “The charges are only a couple of days old, and I have not seen a single piece of evidence, discovery or police reports,” he said. “I look forward to reviewing the case at the appropriate time.” Tuesday’s announcement is part of a broader push from Hochul to counter Republican criticisms that Democrats in New York are soft on public safety issues, an issue that hurt her party in the 2022 midterm elections and has remained a consistent talking point for the GOP. Earlier this year, Hochul signed off on a handful of policies aimed at cracking down on retail theft, including increased criminal penalties for assaulting retail workers, new funding for law enforcement teams dedicated to retail theft and tax credits for businesses to install security cameras. She also approved policies that allow prosecutors to combine the value of stolen goods when filing larceny charges and made it easier to criminally charge third-party sellers of stolen goods. Retail theft has also been a concern elsewhere. Videos of brazen shoplifting crews rampaging through stores have been widely shared on social media, fueling widespread frustration that retail crime is rampant and unpunished. Earlier this month, California voters overwhelmingly passed a tough-on-crime ballot measure that makes shoplifting a felony for repeat offenders again. The measure partly rolled back a progressive law passed by voters a decade ago downgrading several nonviolent crimes to misdemeanors, including theft under $950 in value. Associated Press reporter Anthony Izaguirre in Albany contributed to this story. Follow Philip Marcelo at twitter.com/philmarcelo .